DIRECT - Innovative Medicines Initiative:
DIabetes REsearCh on patient straTification

News, Events, Presentations and Publications

DIRECT Newsletter 2019

Download DIRECT Newsletter as PDF document


EU General Data Protection Regulation

Read more

About IMI More informations

The project “DIabetes REseraCh on patient straTification (DIRECT)” has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115317, resources of which are composed of financial contribution from European Union`s Seventh Framework programme (FP7/2007-2013) and EFPIA companies´ in kind contribution.

The website reflects only the author´s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.

DIRECT Participants More informations

The DIRECT proposal has been published in the third call for proposals of the Innovative Medicines Initiative (IMI), which is part of the EU Seventh Framework Programme (FP7).

DIRECT is a pan-European consortium on pre-competitive research in diabetes funded by the Innovative Medicines Initiative (IMI). Leading European diabetes experts from twenty academic research institutions and five pharmaceutical research organizations are planning to officially launch the DIRECT project in February, 2012. Project duration will be seven years.

In the DIRECT consortium we propose to identify biomarkers and define subtypes with rapid diabetes development and progression as well as altered response to diabetes treatment. Furthermore, we will identify, develop and use surrogate response biomarkers that reflect the underlying disease progression in clinical trials.

The DIRECT consortium addresses two fundamental areas of heterogeneity of diabetes:

  • The rate at which people´s glycaemia deteriorates either from pre-diabetes to diabetes, or through diabetes with increasing treatment requirements
  • The extent to which certain therapeutic interventions (either drug or surgical) results in improvement in glycaemia.

This 7-year project is divided into two phases, a discovery phase and a validation and clinical trial phase. The discovery phase will be undertaken largely in the first 3 years, with validation and clinical trials in years 4 to 7.

In accordance with the IMI research agenda the DIRECT consortium offers considerable potential to achieve major progress towards a personalized medicines approach for the treatment of type 2 diabetes.

The close cooperation of academic teams and pharmaceutical companies in the DIRECT project will provide a unique platform of expertise of a Public-Private-Partnership between the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to persistently improve industrial competitiveness and Public Health in Europe.

For more information please see website of IMI, EFPIA and the European Commission

  • Coordination Team: Sanofi-Aventis Deutschland (H. Rütten)
    • Lilly Deutschland (I. Pavo)
    • University of Dundee (E. Pearson)
  • 26 partners from ten European countries
  • Five pharmaceutical companies
  • 21 academic institutions
  • Project start: February 01, 2012
  • Project duration: Seven years
  • Estimated project budget: 45 Mio EURO
  • Objective: Diabetes research on patient stratification
  • DIRECT press release about project start published on February 22, 2012